Eupraxia Pharmaceuticals Inc. Overview
Pro stress-test →Eupraxia Pharmaceuticals is a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need. The company is focused on advancing EP-104GI, with robust response in the highest dose cohort after 36 weeks following a single treatment in eosinophilic esophagitis (EoE), backed by recent capital raises.
Strategic Profile
Pro stress-test →Eupraxia develops EP-104IAR for intra-articular injections for osteoarthritis and EP-104GI for submucosal injections in the GI tract for indications such as eosinophilic esophagitis. The company completed a $63.2 million public offering in February 2026 and is well-capitalized into H2 2028 with over $140 million cash.
Competitive Landscape
Pro stress-test →Eupraxia competes in the localized GI therapeutics space against companies developing treatments for eosinophilic esophagitis and other gastrointestinal disorders. Key therapeutic areas include EoE treatments (where companies like Adlon Therapeutics, Gossamer Bio, and others operate) and osteoarthritis (a large, crowded market). Eupraxia's differentiation lies in its Diffusphere technology enabling prolonged, hyper-targeted local delivery.
Industry Context
Eupraxia Pharmaceuticals Inc. operates in Localized GI drug delivery / Gastrointestinal therapeutics.
Key facts
Founded: N/A · Headquarters: Vancouver, Canada · Employees: N/A · Revenue: N/A · Market cap: N/A